{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:27:36Z","timestamp":1757618856434,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2020,2,20]]},"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1136\/ejhpharm-2020-002218","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T17:25:20Z","timestamp":1583774720000},"page":"234-236","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Daptomycin in combination with rosuvastatin induced blood creatine phosphokinase elevation"],"prefix":"10.1136","volume":"28","author":[{"given":"Mefk\u00fcre","family":"Durmu\u015f","sequence":"first","affiliation":[{"name":"Clinical pharmacy, Inonu University, Malatya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-4555","authenticated-orcid":false,"given":"\u00d6mer Faruk","family":"Bah\u00e7ecio\u011flu","sequence":"additional","affiliation":[{"name":"Clinical pharmacy, Inonu University, Malatya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"G\u00f6k","sequence":"additional","affiliation":[{"name":"Clinical pharmacy, Inonu University, Malatya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"2025090703124907000_28.4.234.1","unstructured":"Cubicin\u00ae . Daptomycin for injection: US prescribing information. Lexington, MA: Cubist Pharmaceuticals Inc, 2007."},{"key":"2025090703124907000_28.4.234.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1500-y"},{"key":"2025090703124907000_28.4.234.3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/dmdi-2012-0033","article-title":"Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability","volume":"28","author":"Golightly","year":"2013","journal-title":"Drug Metabol Drug Interact"},{"key":"2025090703124907000_28.4.234.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02910-14"},{"key":"2025090703124907000_28.4.234.5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy","volume":"67","author":"Dare","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025090703124907000_28.4.234.6","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M085"},{"key":"2025090703124907000_28.4.234.7","doi-asserted-by":"publisher","DOI":"10.1086\/600039"},{"key":"2025090703124907000_28.4.234.8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-014-0041-y","article-title":"Effect of concomitant 3-hydroxy-3-methyl-glutarylcoa reductase inhibitor therapy on creatine phosphokinase levels and mortality among patients receiving daptomycin: retrospective cohort study","volume":"3","author":"McConnell","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2025090703124907000_28.4.234.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"2025090703124907000_28.4.234.10","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1298"},{"key":"2025090703124907000_28.4.234.11","first-page":"286","article-title":"Dose-independent daptomycin associated rhabdomyolysis: case report","volume":"9","author":"Metwali","year":"2018","journal-title":"J Basic Clin Pharma"},{"key":"2025090703124907000_28.4.234.12","doi-asserted-by":"publisher","DOI":"10.1097\/01.idc.0000219054.28051.b4"},{"key":"2025090703124907000_28.4.234.13","doi-asserted-by":"publisher","DOI":"10.2165\/0129784-200808060-00004"},{"key":"2025090703124907000_28.4.234.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.555482"},{"key":"2025090703124907000_28.4.234.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2008.02.019"},{"key":"2025090703124907000_28.4.234.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.02.007"},{"key":"2025090703124907000_28.4.234.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488409787236056","article-title":"Rosuvastatin induced rhabdomyolysis in a low risk patient: a case report and review of the literature","volume":"4","author":"Khan","year":"2009","journal-title":"Curr Clin Pharmacol"},{"key":"2025090703124907000_28.4.234.18","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.1041051","article-title":"Rosuvastatin (Crestor) and rhabdomyolysis","volume":"171","author":"Wooltorton","year":"2004","journal-title":"CMAJ"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2020-002218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:12:58Z","timestamp":1757239978000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2020-002218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,23]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/ejhpharm-2020-002218"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2020-002218","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}